{
    "title": "114_hr639",
    "content": "The Act titled \"Improving Regulatory Transparency for New Medical Therapies Act\" amends the Federal Food, Drug, and Cosmetic Act regarding the scheduling of substances in new FDA-approved drugs. Approval of a drug under the Controlled Substances Act will not take effect until the interim final rule controlling the drug is issued. The term 'date of approval' for an application means the later of the approval date under subsection (c) or the issuance date of the interim final rule controlling the drug. Approval of a biological product under the Controlled Substances Act will not take effect until the interim final rule controlling the product is issued. The date of approval for a biological product under the Controlled Substances Act is determined by the later of the application approval date or the issuance date of the interim final rule controlling the product. Approval of animal drugs under the Federal Food, Drug, and Cosmetic Act is also affected if the Secretary intends to recommend controls under the CSA. The Controlled Substances Act dictates the date of approval for biological products, which is determined by the application approval date or the issuance date of the interim final rule. Conditional approval of drug applications may be affected if the Secretary intends to recommend controls under the CSA. The Controlled Substances Act determines the date of approval for biological products based on the application approval date or the issuance date of the interim final rule. Conditional approval of drug applications may be impacted if the Secretary plans to recommend controls under the CSA. The Secretary notifies the requester of intent to issue a scientific evaluation under the Controlled Substances Act. Approval for new animal drugs is delayed until the interim final rule is issued. Newly approved drugs will be scheduled accordingly under the Controlled Substances Act. The Controlled Substances Act allows for the scheduling of newly approved drugs based on recommendations from the Secretary of Health and Human Services. The Attorney General must issue an interim final rule within 90 days of receiving the necessary evaluations and recommendations. The Secretary of Health and Human Services has approved an application for a drug under specific acts. The Attorney General must issue an interim final rule promptly, allowing for comments and hearings. Additionally, there is an amendment to extend the patent term for certain drug products. The Secretary of Health and Human Services has approved a drug application under specific acts, and if the Secretary intends to recommend controls under the Controlled Substances Act, the drug product will be considered approved for commercial marketing or use within a specified period. The Secretary of Health and Human Services has approved a drug application under certain acts, and if controls are recommended under the Controlled Substances Act, the drug will be approved for commercial use within a set timeframe. Additionally, for registration to manufacture a controlled substance for clinical trials, the Attorney General must register the applicant within 180 days of application acceptance. The Attorney General must register an applicant within 90 days for manufacturing a controlled substance for clinical trials. Additionally, re-exportation among members of the European Economic Area is addressed in the Controlled Substances Import and Export Act. The Controlled Substances Import and Export Act allows for re-exportation of controlled substances among members of the European Economic Area, with specific conditions to be met by each subsequent country involved. The Controlled Substances Import and Export Act allows for re-exportation of controlled substances among members of the European Economic Area, with specific conditions to be met by each subsequent country involved. This includes documentation and information delivery to the Attorney General within 30 days of re-exportation. Additionally, there are limitations on regulations that may impede re-exportation of certain controlled substances. The Controlled Substances Import and Export Act prohibits regulations that hinder re-exportation of controlled substances among European Economic Area countries, including restrictions on timeframes and information disclosure prior to exportation. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}